Congressi ANCE Maggio-Giugno 2017
NEWS ANCE Giuseppina De Benedittis
Rubriche
Punteggi predittivi per aiutare nella scelta terapeutica: lo score PRECISE DAPT
Punteggi predittivi per aiutare nella scelta terapeutica: lo score PRECISE DAPT Un aspetto da tempo dibattuto in cardiologia è costituito dalla durata della doppia aggregazione antipiastrinica (DAPT), ovvero l’aggiunta all’acido acetilsalicilico di una...
Newsletter ANCE: Comunicato per i soci
REGISTRATI ALLA NEWSLETTER ANCE ISCRIVITI ORA E RICEVERAI IN ANTEPRIMA I NOSTRI AGGIORNAMENTI SU EVENTI E NOVITÀ. L’ANCE si dota di un ulteriore strumento di comunicazione! Abbiamo attivato un servizio di newsletter on-line: fornisce notizie, che arriveranno...
Attività congressuale Gennaio-Aprile 2017
Intensa e proficua attività congressuale ANCE nella prima parte dell’anno presso il Centro Studi di Roma e su tutto il territorio nazionale. Molto apprezzato e seguito, in particolare, il Corso Avanzato che si è tenuto a gennaio presso la sede di Roma nei giorni 27 e...
Seminario Nazionale ANCE 2017
Catania, 19-21 Maggio 2017 Centro Congressi Mercure Catania Excelsior PROGRAMMA DEFINITIVO DEL SEMINARIO
Convocazione Assemblea Soci 2016
I signori dott.ri/proff.ri, Soci ANCE Cardiologia italiana del territorio, sono convocati per l’Assemblea Plenaria dell’Associazione, indetta in Sorrento, presso il Centro Congressi Hilton Sorrento Palace, per il giorno venerdì 7 ottobre 2016 alle ore 8:00, in prima...
Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals
Importance Heart disease (HD) and cancer are the 2 leading causes of death in the United States. During the first decade of the 21st century, HD mortality declined at a much greater rate than cancer mortality and it appeared that cancer would overtake HD as the...
Prognostic Implications of LV Strain Risk Score in Asymptomatic Patients With Hypertensive Heart Disease ONLINE FIRST
Abstract Objectives This study sought to investigate the associations of left ventricular (LV) strain and its serial change with major adverse cardiac events (MACE) in hypertensive heart disease, independent of and incremental to clinical and LV geometric parameters....
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Objective To study the effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin in anticoagulant naïve patients with atrial fibrillation....
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary
In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof...
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54
Background Patients with diabetes appear to be at elevated risk of atherothrombotic events. Objectives The purpose of this study was to determine the effect of antiplatelet therapy with ticagrelor on recurrent ischemic events in patients with diabetes and prior...
Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation
Direct oral anticoagulants (DOACs) have been used in clinical practice in the United States for the last 4 to 6 years. Although DOACs may be an attractive alternative to warfarin in many patients, long-term outcomes of use of these medications are unknown. We...
USO dei NAO
Abstract :The novel oral anticoagulants or direct oral antico- agulants (DOAC) are becoming more common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation (NVAF). The availability of several agents with similar efficacy and safety...
Presentazione del progetto FACT sulla Fibrillazione atriale
Cari soci Ance ho il piacere e l’onore , come anticipato alla riunione dei nostri quadri tenutasi il 22/23 aprile , di comunicarvi l’avvio di un importante studio, in cooperazione con l’AIAC, sulla fibrillazione atriale: lo studio FACT . A fine maggio...
A New Electrocardiographic Marker of Sudden Death in Brugada SyndromeThe S-Wave in Lead I
Abstract Background Risk stratification in asymptomatic patients remains by far the most important yet unresolved clinical problem in the Brugada syndrome (BrS). Objectives This study sought to analyze the usefulness of electrocardiographic parameters as markers of...
Clinical Diagnosis of Electrical vs Anatomic Left Ventricular Hypertrophy
Most physician readers of Aro’s and Chugh’s elegant review of electrical and anatomic types of LVH and the implications will be puzzled by the concepts that electrical LVH (ECG/LVH) and anatomic LVH (echo/LVH and MRI/LVH) might be different entities, and that patients...
Prognostic Usefulness of Proenkephalin in Stable Ambulatory Patients With Heart Failure
Patients with heart failure have a poor prognosis, yet outcomes might be improved by early identification of risk. Proenkephalin (proENK), a novel biomarker, is a stable surrogate marker for endogenous enkephalins and is an independent predictor of heart failure and...
Role of Vorapaxar After Coronary Revascularization
We aim to evaluate the potential benefit and risk of addition of vorapaxar to standard medical therapy in patients who underwent coronary revascularization with either percutaneous coronary revascularization or coronary artery bypass graft surgery. We searched PubMed,...
Parere positivo Fda all’antiaggregante vorapaxar dopo un infarto del miocardio.
Dopo l’endorsement dei giorni scorsi ricevuto dello staff interno dell’Fda, lo scorso 15 gennaio il nuovo antiaggregante orale vorapaxar ha ricevuto il parere positivo degli esperti del Cardiovascular and Renal Drugs Advisory Committee dell’Fda. Con 10 voti a 1, gli...